Standard Chemical & Pharmaceutical Co Ltd (1720) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of Standard Chemical & Pharmaceutical Co Ltd stock TWD 72.51, price TWD 55.10, upside +31.6%, quality 55 out of 100. Rating: undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 5, 2026.
How to read this chart
60‑month range 33.46 TWD – 78.70 TWD · fair‑value band 49.42 TWD – 102.08 TWD · the 55.10 TWD price screens below the 72.51 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 5, 2026.
Follow Standard Chemical & Pharmaceutical Co in your weekly email
Every Wednesday you see whether Standard Chemical & Pharmaceutical Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Standard Chemical & Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sells pharmaceutical products in Taiwan and internationally. The company offers Chinese and western medicines, cosmetics, beverages, general instruments, and medical devices.
Show moreShow less
It also provides western pharmaceuticals for cardiovascular, metabolic, genitourinary and sex steroids, respiratory, musculoskeletal, digestive, nervous, and circulatory systems; anti-infectives and topical medications; and cancer and cancer antiemetic.
In addition, the company offers health food products. Further, it is involved in the manufacture and sale of active pharmaceutical ingredients, as well as veterinary drugs; and sales of medical devices and infant milk powder. It also exports its products.
The company was incorporated in 1967 and is headquartered in Tainan City, Taiwan.
Stock analysis
Standard Chemical & Pharmaceutical Co Ltd (1720) currently trades at 55.10 TWD, while our model-based Fair Value estimate is 72.51 TWD, implying the stock looks roughly 24% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 93.71 TWD per share, and 18 of the 26 models we run sit above the 55.10 TWD price.
Bear case: the Asset-Based group reads lowest at 7.35 TWD, and 8 of the 26 models stay below the price. Data coverage for this calculation is medium.
Scenario range: 49.42 TWD (bear) to 102.08 TWD (bull), the price of 55.10 TWD sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 55/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Standard Chemical & Pharmaceutical Co Ltd reported revenue of 7.0B TWD in FY2025 versus 4.6B TWD in FY2021, a compound +11.1%/yr. Reported net income was 928M TWD in FY2025, compounding +7.0%/yr from FY2021.
Key figures
Market cap 18.3B TWD (≈ $559M) Small · P/E ratio 11.1 · P/S ratio 1.53 · EPS (TTM) 4.98 TWD · Dividend yield 3.3% · Net margin 14.5% · Return on equity 15.4% · Return on assets (EBIT) 11.7% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 60 out of 100 (low confidence).
What moves the price
The share trades about 16% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 32%, 1720 screens cheaper than that median.
Fair Value models
Bear49.42 TWDFair Value 72.51 TWDBull102.08 TWD
Price 55.10 TWD · Upside +31.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (2.71 TWD per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF53.34 TWD73.91 TWD100.88 TWD80
Growth DCF53.37 TWD70.94 TWD92.45 TWD79
Owner Earnings56.33 TWD78.23 TWD106.94 TWD76
All 26 models by family
DCF Models
FCF DCF53.34 TWD73.91 TWD100.88 TWD80
Owner Earnings56.33 TWD78.23 TWD106.94 TWD76
5Y Revenue Exit52.03 TWD77.58 TWD110.12 TWD71
5Y EBITDA Exit62.89 TWD98.16 TWD139.50 TWD74
5Y P/E Exit66.50 TWD104.98 TWD145.76 TWD70
10Y Revenue Exit50.87 TWD72.61 TWD101.75 TWD66
10Y EBITDA Exit58.14 TWD85.30 TWD121.76 TWD68
10Y P/E Exit60.18 TWD89.51 TWD126.02 TWD63
Earnings-Based
Graham-Dodd32.09 TWD106.87 TWD143.06 TWD64
Lynch FV24.21 TWD34.59 TWD44.97 TWD61
PEG = 1.024.21 TWD34.59 TWD44.97 TWD57
EPV38.14 TWD42.12 TWD45.38 TWD73
Dividend Discount
Gordon GGM13.78 TWD23.85 TWD31.74 TWD68
DDM Multi-Stage13.78 TWD21.68 TWD25.58 TWD67
Multiples
P/E Multiple77.87 TWD103.83 TWD129.78 TWD63
P/S Multiple60.17 TWD80.23 TWD100.29 TWD57
P/B Multiple101.58 TWD135.44 TWD169.30 TWD55
EV/EBIT67.21 TWD88.98 TWD110.75 TWD65
EV/EBITDA72.81 TWD96.45 TWD120.09 TWD67
EV/Revenue48.52 TWD68.49 TWD88.47 TWD53
Asset-Based
NCAV (Graham)4.85 TWD7.35 TWD9.19 TWD54
Growth DCF
Growth DCF53.37 TWD70.94 TWD92.45 TWD79
Rev-Margin DCF52.03 TWD77.75 TWD107.91 TWD72
Economic Profit
Residual Income28.88 TWD34.11 TWD45.91 TWD76
ROIC Compounder39.42 TWD45.99 TWD53.33 TWD71
Growth Earnings
Growth-Adj P/E65.60 TWD93.71 TWD121.82 TWD67
The fair value above starts from this blend and is adjusted for dilution from new shares.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.92/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+3.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.3%
Start year 2020 (pandemic). Over 10 years: +7.8% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.5%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+8.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year+5.5%
Dividend (yield on the price)3.3%
Per share before 2011divided by the spin-off factor 1.07
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.5.5% vs 7.0%, steady
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.18% → 19%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+5.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Taiwan: IMF forecast 1.6% a year to 2030, 1.5% from 2016 to 2025) that is about +3.5% a year for the price.
Compare Standard Chemical & Pharmaceutical Co Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks
Beats the industry median on 10/15 measures
Overall it ranks above its industry peers.
Valuation
Quality Score55 · Below median
Fair Value upside+31.6% · Top 25%
Profitability
Return on equity (12 months)15.4% · Top 25%
Return on assets10.6% · Top 25%
Net margin (12 months)19.6% · Top 25%
Operating margin (12 months)21.8% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)2.4% · Below median
Dividend yield (12 months)3.3% · Top 25%
Balance sheet
Debt / equity0.00× · Lowest 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/E (12 months)11.1× · Cheapest 25%
P/B3.00× · Pricier than median
P/S (12 months)3.51× · Pricier than median
Price / free cash flow (fiscal year)18.0× · Cheaper than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Standard Chemical & Pharmaceutical Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/1720
Frequently asked questions
Is Standard Chemical & Pharmaceutical Co Ltd (1720) overvalued or undervalued?
As of Nov 5, 2026, our model estimates a fair value of 72.51 TWD versus a price of 55.10 TWD, about +32% upside (undervalued).
What is the fair value of 1720?
Our model-based fair value for Standard Chemical & Pharmaceutical Co Ltd is 72.51 TWD (as of Nov 5, 2026), built from audited fundamentals. The current price: 55.10 TWD.
What is the quality score of 1720?
Standard Chemical & Pharmaceutical Co Ltd has a Quality Score of 55/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Standard Chemical & Pharmaceutical Co Ltd (1720)?
Our model-based price target is the fair value of 72.51 TWD (as of Nov 5, 2026) from 26 valuation models. Cautious scenario 49.42 TWD, optimistic scenario 102.08 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Standard Chemical & Pharmaceutical Co Ltd stock forecast for 2026?
Our models put fair value at 72.51 TWD, about +32% upside versus a price of 55.10 TWD (undervalued). Cautious scenario 49.42 TWD, optimistic scenario 102.08 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Standard Chemical & Pharmaceutical Co Ltd (1720)?
Standard Chemical & Pharmaceutical Co Ltd reported trailing-twelve-month revenue of about 7.1B TWD (latest available figure, as of Nov 5, 2026).
Does Standard Chemical & Pharmaceutical Co Ltd pay a dividend?
Standard Chemical & Pharmaceutical Co Ltd currently shows a dividend yield of 3.30% relative to its recent price (as of Nov 5, 2026).
How much is the dividend of Standard Chemical & Pharmaceutical Co Ltd (1720) and when is the ex-dividend date?
Standard Chemical & Pharmaceutical Co Ltd pays a dividend of 1.82 TWD per share a year, a dividend yield of 3.3%. The last ex-dividend date was Jul 23, 2026. The payout ratio is 36.5% of earnings. Free cash flow covers the dividend 3.85 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into Standard Chemical & Pharmaceutical Co Ltd (1720)?
For today's price to be fair in a discounted-cash-flow model, Standard Chemical & Pharmaceutical Co Ltd would have to grow free cash flow by +5.1 % per year for five years (discount rate 11.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +10.3 % per year. As of Nov 5, 2026.
What discount rate (WACC) does the fair value of 1720 use?
Our models discount Standard Chemical & Pharmaceutical Co Ltd at 11.8 %: a base by market capitalisation (small), country premium for Taiwan. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Standard Chemical & Pharmaceutical Co Ltd that is +5.1 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.8 %) and the same formula as our fair value.
How much growth has Standard Chemical & Pharmaceutical Co Ltd (1720) delivered so far?
Over the past 5 years revenue at Standard Chemical & Pharmaceutical Co Ltd grew +10.3 % a year. The price currently implies free-cash-flow growth of +5.1 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Standard Chemical & Pharmaceutical Co Ltd (1720) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Standard Chemical & Pharmaceutical Co Ltd (+5.1 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Standard Chemical & Pharmaceutical Co Ltd (1720)?
The free-cash-flow yield on the price is 7.50 %: that much free cash flow Standard Chemical & Pharmaceutical Co Ltd produces per unit of market value. When it exceeds the discount rate of our models (11.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Standard Chemical & Pharmaceutical Co Ltd (1720)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Standard Chemical & Pharmaceutical Co Ltd it is 72.51 TWD per share (as of Nov 5, 2026), against a price of 55.10 TWD. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Standard Chemical & Pharmaceutical Co Ltd stock overvalued or undervalued in 2026?
As of Nov 5, 2026, 1720 trades below its calculated fair value: price 55.10 TWD, fair value 72.51 TWD, a gap of about +32% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 1720?
No. The price is what the market pays today (55.10 TWD); the fair value is what the company's own numbers justify (72.51 TWD). For Standard Chemical & Pharmaceutical Co Ltd the two are 17.41 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Standard Chemical & Pharmaceutical Co Ltd worth?
The market values Standard Chemical & Pharmaceutical Co Ltd at about 18.3B TWD (market capitalisation, as of Nov 5, 2026). Per share that is 55.10 TWD; our models calculate a fair value of 72.51 TWD per share.
What do the bullish and bearish scenarios say about 1720?
Our models span a range for Standard Chemical & Pharmaceutical Co Ltd: cautious scenario 49.42 TWD, base 72.51 TWD, optimistic 102.08 TWD per share (as of Nov 5, 2026, price 55.10 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 1720?
Standard Chemical & Pharmaceutical Co Ltd trades at a price-to-earnings ratio of 11.1 (as of Nov 5, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 72.51 TWD is built from several models across several years. Other multiples: PEG 16.3, P/B 3.0, P/S 3.5, EV/EBITDA 12.0.
What is the PEG ratio of 1720?
The PEG ratio of Standard Chemical & Pharmaceutical Co Ltd is 16.33 (P/E divided by earnings growth, as of Nov 5, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Standard Chemical & Pharmaceutical Co Ltd (1720)?
Balance-sheet figures for Standard Chemical & Pharmaceutical Co Ltd (as of Nov 5, 2026): return on equity 15.4%, debt of 0.00 per unit of equity. They feed the Quality Score of 55/100, which measures business quality independently of the share price.
How far is 1720 from its 52-week high?
Standard Chemical & Pharmaceutical Co Ltd trades at 55.10 TWD, about 16% below its 52-week high of 65.60 TWD and at the low of 55.10 TWD (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 72.51 TWD is for.
Which stocks are comparable to Standard Chemical & Pharmaceutical Co Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Standard Chemical & Pharmaceutical Co Ltd stock attractive at the current price?
The data as of Nov 5, 2026: price 55.10 TWD, calculated fair value 72.51 TWD (+32%), Quality Score 55/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 1720 calculated?
We run Standard Chemical & Pharmaceutical Co Ltd through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 72.51 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Standard Chemical & Pharmaceutical Co Ltd currently trades 24% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Standard Chemical & Pharmaceutical Co Ltd (1720)?
The closing price on Nov 9, 2026 was 55.10 TWD. Our model-based fair value is 72.51 TWD, about +32% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Standard Chemical & Pharmaceutical Co Ltd right now?
Solid quality (55/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (49.42 TWD to 102.08 TWD) leaves room in how you read the outcome.
Where does the earnings growth of Standard Chemical & Pharmaceutical Co Ltd (1720) come from?
Earnings per share at Standard Chemical & Pharmaceutical Co Ltd grew +9.3 % a year from 2014 to 2025. Broken into its drivers: revenue per share +6.4 %, EBIT margin +6.4 %, tax rate −0.7 %, residual (interest, one-offs) −2.7 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Standard Chemical & Pharmaceutical Co Ltd
How large is the market capitalisation of Standard Chemical & Pharmaceutical Co Ltd (1720)?
The market capitalisation of Standard Chemical & Pharmaceutical Co Ltd is 18.3B TWD (≈ $559M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Standard Chemical & Pharmaceutical Co Ltd (1720)?
The price-to-sales ratio of Standard Chemical & Pharmaceutical Co Ltd is 1.53 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Standard Chemical & Pharmaceutical Co Ltd (1720)?
Earnings per share at Standard Chemical & Pharmaceutical Co Ltd are 4.98 TWD (price ÷ EPS = P/E 11.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Standard Chemical & Pharmaceutical Co Ltd (1720)?
The dividend yield of Standard Chemical & Pharmaceutical Co Ltd is 3.3% (payout 36.5%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Standard Chemical & Pharmaceutical Co Ltd (1720)?
The net margin of Standard Chemical & Pharmaceutical Co Ltd is 14.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Standard Chemical & Pharmaceutical Co Ltd (1720)?
The return on equity (ROE) of Standard Chemical & Pharmaceutical Co Ltd is 15.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Standard Chemical & Pharmaceutical Co Ltd (1720)?
On an EBIT basis the return on assets of Standard Chemical & Pharmaceutical Co Ltd is 11.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Standard Chemical & Pharmaceutical Co Ltd (1720)?
The operating margin of Standard Chemical & Pharmaceutical Co Ltd is 21.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Standard Chemical & Pharmaceutical Co Ltd (1720)?
Revenue at Standard Chemical & Pharmaceutical Co Ltd is growing +2.4% versus a year earlier (3y avg +6.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Standard Chemical & Pharmaceutical Co Ltd (1720)?
Earnings per share at Standard Chemical & Pharmaceutical Co Ltd are growing +31.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Standard Chemical & Pharmaceutical Co Ltd (1720) hold?
Standard Chemical & Pharmaceutical Co Ltd holds more cash than debt, 506M TWD net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Standard Chemical & Pharmaceutical Co Ltd in the live analysis
One click puts Standard Chemical & Pharmaceutical Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 5, 2026